benign multiple sclerosis
Recently Published Documents


TOTAL DOCUMENTS

91
(FIVE YEARS 5)

H-INDEX

19
(FIVE YEARS 0)

2021 ◽  
pp. 577650
Author(s):  
Maria Ivanova ◽  
Anastasiya Voronkova ◽  
Vladimir Sukhorukov ◽  
Maria Zakharova


Author(s):  
Recai Turkoglu ◽  
Vuslat Yilmaz ◽  
Ozkan Ozdemir ◽  
Ece Akbayir ◽  
Gulcin Benbir ◽  
...  


Author(s):  
Guillaume Mathey ◽  
Guillaume Pisché ◽  
Marc Soudant ◽  
Sophie Pittion-Vouyovitch ◽  
Francis Guillemin ◽  
...  


2020 ◽  
Vol 267 (12) ◽  
pp. 3508-3517
Author(s):  
Gianna C. Riccitelli ◽  
Elisabetta Pagani ◽  
Alessandro Meani ◽  
Paola Valsasina ◽  
Paolo Preziosa ◽  
...  


Experimed ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 105-112
Author(s):  
Melis Sen ◽  
◽  
Ece Akbayir ◽  
Recai Turkoglu ◽  
Erdem Tuzun ◽  
...  






2019 ◽  
Vol 9 (4) ◽  
pp. e01259 ◽  
Author(s):  
Laura Melanie Schaefer ◽  
Jana Poettgen ◽  
Anja Fischer ◽  
Stefan Gold ◽  
Jan‐Patrick Stellmann ◽  
...  


2019 ◽  
Vol 90 (7) ◽  
pp. 761-767 ◽  
Author(s):  
Loes Crielaard ◽  
Andrius Kavaliunas ◽  
Ryan Ramanujam ◽  
Tomas Olsson ◽  
Jan Hillert ◽  
...  

ObjectiveBenign multiple sclerosis (BMS) is often defined by the Expanded Disability Status Scale (EDSS) score of ≤3.0 after ≥15 years of disease duration. This classification’s clinical relevance remains unclear as benign patients may suffer other impairments and advance towards a progressive course, prompting our objective to holistically investigate factors associated with BMS and its long-term prognosis.MethodsBenign cases were identified in the Swedish Multiple Sclerosis registry. Baseline clinical data, demographic features and influence of multiple sclerosis (MS) major risk alleles on likelihood of benign course were investigated. Physical disability (EDSS), cognitive function (Symbol Digit Modalities Test; SDMT) and self-reported and socioeconomic differences between benign and non-benign patients were evaluated using generalised estimation equations models.Results11222 patients (2420 benign/8802 non-benign) were included. Benign patients were more likely to be female and younger at MS onset, have fewer relapses within the first two and 5 years from onset and fully recover from the first relapse (p<0.001). No association between human leucocyte antigen (HLA) DRB1*15:01 carriership (OR: 0.97, 95% CI: 0.86 to 1.09) or HLA-A*02:01 lacking (OR: 0.99, 95% CI: 0.87 to 1.11) and benign/non-benign was found. Non-benign patients accumulated an extra 0.04 (95% CI 0.03 to 0.04, p<0.001) EDSS score/year, lost an extra 0.3 (95% CI − 0.39 to − 0.18, p<0.001) SDMT score/year and deteriorated faster in self-reported impact and socioeconomic measures (p<0.001).ConclusionPatients with BMS have a better disease course as they progress more slowly at the group level in all respects. Lack of an association with major genetic risk factors indicates that MS course is most likely influenced by either environmental factor(s) or genetic factors outside the HLA region.



Sign in / Sign up

Export Citation Format

Share Document